Interventional cardiology;Cardiología intervencionista

Revista Espanola de Cardiologia

Volumn 61, Issue SUPPL. 1, 2008, Pages 72-85

  Albarran Gonzalez Trevilla, Agustín ^a   Pinar, Eduardo ^b   Baz, José A ^c   Mauri, Josepa ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Drug eluting stents; Percutaneous coronary intervention; Percutaneous noncoronary intervention; Stents

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; CORONARY STENT; DRUG ELUTING STENT; HEART FORAMEN OVALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION; THROMBOSIS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION;

EID: 46649109581     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Hernández Antolín RA, Fernández-Vázquez F, Moreu BJ, López Palop R. Cardiología intervencionista 2006. Rev Esp Cardiol. 2007;60 Supl 1:19-32.
2. Thuesen L, Kelbaek H, Kløvgaard L, Helqvist S, Jørgensen E, Aljabbari S, et al. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT). Am Heart J. 2006;152:1140-5.
3. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín RA, Gómez-Hospital JA, et al. Eficacia de la implantación del stent recubierto de rapamicina en pacientes diabéticos con vasos muy pequeños (≤ 2,25 mm). Subanálisis del estudio DIABETES. Rev Esp Cardiol. 2006;59:1000-7.
4. Velazquez M, Hernandez F, Garcia J, Andreu J. Trombosis aguda de stent tras la realización de una ergometría precoz postimplante de stent. Rev Esp Cardiol. 2007;60:324-6.
5. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-55.
6. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-814.
7. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91.
8. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-9.
9. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-97.
10. Kastrati A, Mehilli J, Pache J, Valgimigli M, Kelbaek H. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-9.
11. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
12. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-19.
13. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation. 2006;114:2154-62.
14. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol. 2007;49:1924-30.
15. Laarman GJ, Suttorp MJ, Dirksen MT, Kremer K, Gonçalves D, Tedeschi AL, Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105-13.
16. Win HK, Caldera AE, Maresh K, López J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001-9.
17. Trabattoni D, Fabbiocchi F, Montorsi P, Ravagnani P, Galli S, Teruzzi G, et al. Stent thrombosis after sirolimus- and paclitaxel-eluting stent implantation in daily clinical practice: Analysis of a single center registry. Catheter Cardiovasc Interv. 2007;70:415-21.
18. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-8.
19. Garcia-Tejada J, Gutierrez H, Albarran A, Hernández F, Velázquez T, Rodríguez S, et al. Carbo-stent liberador de tacrolimus Janus®. Resultados inmediatos y seguimiento clínico a medio plazo. Rev Esp Cardiol. 2007;60:197-200.
20. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41.
21. De Ribamar CJ Jr, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, et al. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J. 2007;153:297-303.
22. Grines CL, Bonow RO, Casey DE, Jr. Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813-8.
23. Erbel R, di Mario C, Bartunek J, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369:1869-75.
24. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
25. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355:1093-104.
26. Diaz de la Llera LS, Ballesteros S, Nevado J, Fernández M, Villa M, Sánchez A, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J. 2007;154:164-6.
27. Pasceri V, Patti G, Speciale G, Pristipino C, Richichi G, Di Sciascio G, et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. 2007;153:749-54.
28. Zhang F, Ge J, Qian J, Fan B, Wang Q, Ge L, et al. Sirolimus-Eluting Stents in Real-World Patients With ST-Segment Elevation Acute Myocardial Infarction. Int Heart J. 2007;48:303-11.
29. Gogo PB Jr, Dauerman HL, Mulgund J, Ohman EM, Patel MR, Cohen DJ, et al. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol. 2007;99:1222-6.
30. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908-17.
31. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.
32. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-16.
33. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-63.
34. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362-8.
35. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-82.
36. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-8.
37. Barlis P, Tanigawa J, Kaplan S, Di Mario C. Complex coronary interventions: unprotected left main and bifurcation lesions. J Interv Cardiol. 2006;19:510-24.
38. Lopez-Palop R, Moreu J, Fernandez-Vazquez F, Hernández- Antolín RA. Registro Español de Hemodinámica y Cardiología Intervencionista. XV Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2005). Rev Esp Cardiol. 2006;59:1146-64.
39. Baz J, Mauri J, Albarrán A, Pinar E. Registro Español de Hemodinámica y Cardiología Intervencionista. XVI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2006). Rev Esp Cardiol. 2007;60:1263-89.
40. Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Savini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol. 2006;98:54-9.
41. Chieffo A, Morici N, Maisano F, Shinichi W, Hiroaki K, Keisuke U. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. 2006;113:2542-7.
42. Migliorini A, Moschi G, Giurlani L, Valenti R, Vergara R, Parodi G. Drug-eluting stent supported percutaneous coronary intervention for unprotected left main disease. Catheter Cardiovasc Interv. 2006;68:225-30.
43. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc. 2007;138:652-5.
44. Chieffo A, Park SJ, Valgimigli M, Kim YH, Daemen J, Sheiban I, et al. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation. 2007;116:158-62.
45. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, García- García HM, Polad J, Tsuchida K, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol. 2006;47:1530-7.
46. Price MJ, Cristea E, Sawhney N, Kao JA, Moses JW, Leon MB, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol. 2006;47:871-7.
47. Pan M, Suarez DL, Medina A, Romero M, Delgado A, Segura J, et al. Ecografía intracoronaria durante el seguimiento en la valoración de stents liberadores de rapamicina para el tratamiento de las lesiones en bifurcación: implicaciones técnicas. Rev Esp Cardiol. 2005;58:1278-86.
48. Kaplan S, Barlis P, Dimopoulos K, La Manna A, Goktekin O, Galassi A, et al. Culotte versus T-stenting in bifurcation lesions: immediate clinical and angiographic results and midterm clinical follow-up. Am Heart J. 2007;154:336-43.
49. Diaz de la Llera LS, Ballesteros SM, Guisado A, Aguilera A, Campos A, Sánchez A, et al. Tratamiento de las lesiones bifurcadas mediante técnica de crush T stenting: resultados inmediatos y a medio plazo. Rev Esp Cardiol. 2006;59:458-64.
50. De la Torre Hernandez JM, Ruiz-Lera M, Fernandez-Friera L. et al. Aplicación prospectiva de un valor de corte de área luminal mínima por ecografía intravascular en la evaluación de lesiones intermedias del tronco. Rev Esp Cardiol. 2007;60:811-6.
51. Medina A, Suárez de Lezo J, Pan M. Una clasificación simple de las lesiones coronarias en bifurcación. Rev Esp Cardiol. 2006;59:183.
52. Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation. 2006;114:1955-61.
53. Brunel P, Lefevre T, Darremont O, Louvard Y. Provisional T-stenting and kissing balloon in the treatment of coronary bifurcation lesions: results of the French multicenter TULIPE study. Catheter Cardiovasc Interv. 2006;68:67-73.
54. Koo BK, Kang HJ, Youn TJ et al. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol. 2005;46:633-7.
55. Chen JL, Gao RL, Yang YJ, Qiao SB, Qin XW, Yao M, et al. Short and long-term outcomes of two drug eluting stents in bifurcation lesions. Chin Med J (Engl ). 2007;120:183-6.
56. Hoye A, Iakovou I, Ge L, Van Mieghem CA, Ong AT, Cosgrave J, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006;47:1949-58.
57. Ormiston JA, Webster MW, El Jack S, McNab D, Plaumann SS. Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies. Catheter Cardiovasc Interv. 2006;67:49-55.
58. Aziz S, Stables RH, Grayson AD, Perry RA, Ramsdale DR. Percutaneous coronary intervention for chronic total occlusions: improved survival for patients with successful revascularization compared to a failed procedure. Catheter Cardiovasc Interv. 2007;70:15-20.
59. Soon KH, Selvanayagam JB, Cox N, Kelly AM, Bell KW, Lim YL. Percutaneous revascularization of chronic total occlusions: review of the role of invasive and non-invasive imaging modalities. Int J Cardiol. 2007;116:1-6.
60. Migliorini A, Moschi G, Vergara R, Parodi G, Carrabba N, Antoniucci D, et al. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion. Catheter Cardiovasc Interv. 2006;67:344-8.
61. Werner GS, Schwarz G, Prochnau D, Fritzenwanger M, Krack A, Betge S, et al. Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc Interv. 2006;67:1-9.
62. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006;114:921-8.
63. Suttorp MJ, Laarman GJ; PRISON III study investigators. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. Am Heart J. 2007;154:432-5.
64. Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J. 2005;26:2630-6.
65. Ozawa N. A new understanding of chronic total occlusion from a novel PCI technique that involves a retrograde approach to the right coronary artery via a septal branch and passing of the guide-wire to a guiding catheter on the other side of the lesion. Catheter Cardiovasc Interv. 2006;68:907-13.
66. Surmely JF, Katoh O, Tsuchikane E, Nasu K, Suzuki T. Coronary septal collaterals as an access for the retrograde approach in the percutaneous treatment of coronary chronic total occlusions. Catheter Cardiovasc Interv. 2007;69:826-32.
67. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolín R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175-83.
68. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Costa MA, Alfonso F, Gómez-Hospital JA, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol. 2006;47:2172-9.
69. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Alfonso F, Hernández-Antolín R, SanMartín M, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J. 2007;28:1946-52.
70. Lemos PA, Arampatzis CA, Hoye A. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am J Cardiol. 2005;95:167-72.
71. Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399-402.
72. Okabe T, Mintz GS, Buch AN, Roy P, Hong YJ, Smith KA, et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol. 2007;100:615-20.
73. Cook S, Wenaweser P, Togni M, Billinger M, Morgar C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-34.
74. Siqueira DA, Abizaid AA, Costa JR, Feres F, Mattos LA, Staico R, et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J. 2007;28:1304-9.
75. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006;113:414-9.
76. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol. 2006;48:421-9.
77. Pijls NH, Van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, Van't Veer M, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49:2105-11.
78. Kubo T, Imanishi T, Takarada S, Kuroi A, Lleno S, Yamano T, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007;50:933-9.
79. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007;99:1033-8.
80. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761-91.
81. Goldstein JA, Gallagher MJ, O'Neill WW, Ross MA, O'Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol. 2007;49:863-71.
82. Hoffmann U, Nagurney JT, Moselewski F, Pena A, Ferencik M, Chae CU, et al. Coronary multidetector computed tomography in the assessment of patients with acute chest pain. Circulation. 2006;114:2251-60.
83. Onuma Y, Tanabe K, Nakazawa G, Aoki J, Nakajima H, Ibukuro K, et al. Noncardiac findings in cardiac imaging with multidetector computed tomography. J Am Coll Cardiol. 2006;48:402-6.
84. Suárez DL, Herrera C, Pan M, Romero M, Pavlovic D, Segura J, et al. Tratamiento regenerativo en pacientes con infarto agudo anterior revascularizado y función ventricular deprimida. Rev Esp Cardiol. 2007;60:357-65.
85. Nadal-Ginard B, Torella D, Ellison G. Medicina regenerativa cardiovascular en la encrucijada. Es urgente basar los ensayos clínicos sobre terapia celular en datos sólidos obtenidos en animales experimentales relevantes para los humanos. Rev Esp Cardiol. 2006;59:1175-89.
86. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17-20.
87. Lechat P, Mas JL, Lascault G Loron P, Therad M, Kilmczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148-52.
88. Adler E, Love B, Giovannone S, et al. Correlation or causation: untangling the relationship between patent foramen ovale and migraine. Curr Cardiol Rep. 2007;9:7-12.
89. Slavin L, Tobis JM, Rangarajan K, Dae C, Krivokapich J, Liebeskind DS. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol. 2007;99:1316-20.
90. Rocca MA, Ceccarelli A, Falini A, Colombo B, Tortorella P, Bernasconi L, et al. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke. 2006;37:1765-70.
91. Schwerzmann M, Nedeltchev K, Meier B. Patent foramen ovale closure: a new therapy for migraine. Catheter Cardiovasc Interv. 2007;69:277-84.
92. Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation. 2007;116:677-82.
93. Shammas NW, Dippel EJ, Harb G, Egts S, Jerin M, Stoakes P, et al. Interatrial septal defect closure for prevention of cerebrovascular accidents: impact on recurrence and frequency of migraine headaches. J Invasive Cardiol. 2007;19:257-60.